Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function

被引:13
作者
Sælen, MG
Prosch, LK
Gudmundsdottir, H
Dyrbekk, D
Hunderi, OH
Arnesen, E
Paulsen, D
Skjonsberg, H
Os, I [1 ]
机构
[1] Ullevaal Univ Hosp, Dept Nephrol, N-0407 Oslo, Norway
[2] Univ Oslo, Dept Pharmacotherapeut, Oslo, Norway
[3] Vestfold HF, Tensberg, Norway
[4] Ostfold HF, Fredrikstad, Norway
[5] Innlandet HF Elverum, Elverum, Norway
[6] Innlandet HF Lillehammer, Lillehammer, Norway
[7] Akershus Univ Hosp, Nordbyhagen, Norway
关键词
antihypertensive drugs; blood pressure control; chronic renal failure; diabetic kidney disease;
D O I
10.1080/08037050510008959
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
This study compared the use of antihypertensive treatment and blood pressure ( BP) controls between patients with diabetic kidney disease (DK+) and patients with non-diabetic kidney disease (DK-) exhibiting moderate-to-severe chronic renal failure who did not need renal replacement therapy. A cross-sectional survey included all renal patients with s-creatinine at >= 200 mu mol/l attending regular control sessions at six renal units in Norway. Of the 351 patients included, 73 (20.8%) were DK+. The proportion reaching a BP goal of <130/80 mmHg was similar in DK+ and DK- (14.1% vs 13.6%, p=0.92), while 38% and 39% achieved a BP of <140/90 mmHg, respectively. The systolic BP goal was more difficult to achieve than the diastolic BP goal in DK+ patients (35% vs 15%) despite a mean of three different types of drugs being used. Loop diuretics and beta-adrenergic-receptor antagonists were the most frequently prescribed drugs, and the use of angiotensin-converting enzyme inhibitors or angiotensin-II-receptor antagonists declined when renal function deteriorated, from 80% to 0% and from 66% to 20% in the DK+ and DK- groups, respectively (p=0.001). Thus, despite the use of multiple antihypertensive drugs, controlling BP-especially the systolic BP-is difficult in high-risk patients with chronic renal failure caused by diabetic kidney disease.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 33 条
[1]   2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension [J].
Afridi, I ;
Canny, J ;
Yao, CH ;
Christensen, B ;
Cooper, RS ;
Kadiri, S ;
Hill, S ;
Kaplan, N ;
Kuschnir, E ;
Lexchin, J ;
Mendis, S ;
Poulter, N ;
Psaty, BM ;
Rahn, KH ;
Sheps, SG ;
Whitworth, J ;
Yach, D ;
Bengoa, R ;
Ramsay, L ;
Kaplan, N ;
Mendis, S ;
Poulter, N ;
Whitworth, J .
JOURNAL OF HYPERTENSION, 2003, 21 (11) :1983-1992
[2]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[3]   Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy [J].
Berl, T ;
Hunsicker, LG ;
Lewis, JB ;
Pfeffer, MA ;
Porush, JG ;
Rouleau, JL ;
Drury, PL ;
Esmatjes, E ;
Hricik, D ;
Parikh, CR ;
Raz, I ;
Vanhille, P ;
Wiegmann, TB ;
Wolfe, BM ;
Locatelli, F ;
Goldhaber, SZ ;
Lewis, EJ .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) :542-549
[4]   PROGRESSIVE RENAL-DISEASE - ROLE OF RACE AND ANTIHYPERTENSIVE MEDICATIONS [J].
BRAZY, PC ;
FITZWILLIAM, JF .
KIDNEY INTERNATIONAL, 1990, 37 (04) :1113-1119
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   Prevalence of high blood pressure and elevated serum creatinine level in the United States -: Findings from the Third National Health and Nutrition Examination Survey (1988-1994) [J].
Coresh, J ;
Wei, L ;
McQuillan, G ;
Brancati, FL ;
Levey, AS ;
Jones, C ;
Klag, MJ .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (09) :1207-1216
[9]   Implementation of guidelines for the prevention of diabetic nephropathy [J].
Fagerudd, J ;
Forsblom, C ;
Pettersson-Fernholm, K ;
Groop, PH .
DIABETES CARE, 2004, 27 (03) :803-804
[10]  
GISEN, 1996, LANCET, V349, P1857